Evidence map›Paper›PMID 30241183›Full record

ArticleJournal of global oncology2018

Shared Decision-Making in Patients With Prostate Cancer in Japan: Patient Preferences Versus Physician Perceptions.

Ulrike Schaede, Jörg Mahlich, Masahiko Nakayama, Hisanori Kobayashi, Yuriko Takahashi, Katsuhiko Saito, Hiroji Uemura, Masayuki Tokumitsu, Kazutake Yoshizawa

Abstract read
In one paragraph

Article in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Comparative analysis of treatment decision-making in patients with localized prostate and cervical cancer: what influences receiving surgery or radiotherapy?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Information, deliberation, and decisional control preferences for participation in medical decision-making and its influencing factors among Chinese cancer patients.Health expectations : an international journal of public participation in health care and health policy · 2021
    Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ulrike SchaedeUlrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan.
Jörg MahlichUlrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan.
Masahiko NakayamaUlrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan.
Hisanori KobayashiUlrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan.
Yuriko TakahashiUlrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan.
Katsuhiko SaitoUlrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan.
Hiroji UemuraUlrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan.
Masayuki TokumitsuUlrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan.
Kazutake YoshizawaUlrike Schaede, University of California at San Diego, San Diego, CA; Jörg Mahlich, Janssen Pharmaceutical K.K., Tokyo, Japan, and University of Düsseldorf, Düsseldorf, Germany; Masahiko Nakayama, Hisanori Kobayashi, and Kazutake Yoshizawa, Janssen Pharmaceutical K.K.; Yuriko Takahashi and Katsuhiko Saito, Anterio, Tokyo; Hiroji Uemura, Yokohama City University, Medical Center, Yokohama; and Masayuki Tokumitsu, Kitasaito Hospital, Ashikawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article adds the Japanese perspective to our knowledge of shared decision-making (SDM) preferences by surveying patients with prostate cancer (PCA) and physicians in Japan. In 2015, 103 Japanese patients with PCA were asked about their SDM preferences by using an Internet-based 5-point-scale questionnaire. Concurrently, 127 Japanese physicians were surveyed regarding their perceptions of patient preferences on SDM. Drivers of preferences and perceptions were analyzed using univariable ordinal logistic regression and graphing the fitted response probabilities. Although 41% of both patients and physicians expressed and expected a desire for active involvement in treatment decisions (a higher rate than in a similar study for the United States in 2001), almost half the Japanese patients preferred SDM, but only 33% of physicians assumed this was their choice. That is, 29% of Japanese physicians underestimated patients' preference for involvement in making treatment decisions. Patients with lower health-related quality of life (as measured by the Functional Assessment of Cancer Therapy-Prostate [FACT-P]) expressed a stronger preference for SDM. The study shows that the worse the medical situation, the more patients with PCA prefer to be involved in the treatment decision, yet physicians tend to underestimate the preferences of their patients. Perhaps in contrast to common assumptions, Japanese patients are as interested in being involved in decision making as are patients in the United States.

Indexed as

Decision MakingPhysician-Patient RelationsAgedAged, 80 and overAttitude of Health PersonnelHumansJapanMaleMiddle AgedPatient ParticipationPatient PreferencePhysiciansProstatic NeoplasmsQuality of LifeSurveys and Questionnaires

Identifiers

PMID30241183
PMCPMC6180796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.